Literature DB >> 25312590

Vasculitides and the Complement System: a Comprehensive Review.

Maria Sole Chimenti1, Eleonora Ballanti2, Paola Triggianese2, Roberto Perricone2.   

Abstract

Systemic vasculitides are a group of rare diseases characterized by inflammation of the arterial or venous vessel wall, causing stenosis or thrombosis. Clinical symptoms may be limited to skin or to other organs or may include multiple manifestations as systemic conditions. The pathogenesis is related to the presence of leukocytes in the vessels and to the IC deposition, which implies the activation of the complement system (CS) and then the swelling and damage of vessel mural structures. The complement system (CS) is involved in the pathogenesis of several autoimmune diseases, including systemic vasculitides. This enzymatic system is a part of the innate immune system, and its function is linked to the modulation of the adaptive immunity and in bridging innate and adaptive responses. Its activation is also critical for the development of natural antibodies and T cell response and for the regulation of autoreactive B cells. Complement triggering contributes to inflammation-driven tissue injury, which occurs during the ischemia/reperfusion processes, vasculitides, nephritis, arthritis, and many others diseases. In systemic vasculitides, a group of uncommon diseases characterized by blood vessel inflammation, the contribution of CS in the development of inflammatory damage has been demonstrated. Treatment is mainly based on clinical manifestations and severity of organ involvement. Evidences on the efficacy of traditional immunosuppressive therapies have been collected as well as data from clinical trials that involve the modulation of the CS. In particular in small-medium-vessel vasculitides, the CS represents an attractive target. Herein, we reviewed the pathogenetic role of CS in these systemic vasculitides as urticarial vasculitis, ANCA-associated vasculitides, anti-glomerular basement membrane disease, cryoglobulinaemic vasculitides, Henoch-Schönlein purpura/IgA nephropathy, and Kawasaki disease and therefore its potential therapeutic use in this context.

Entities:  

Keywords:  ANCA; Anti-complement therapy; Complement system; Cryoglobulinemia; Urticarial vasculitis; Vasculitides

Mesh:

Substances:

Year:  2015        PMID: 25312590     DOI: 10.1007/s12016-014-8453-8

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   10.817


  86 in total

1.  The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis.

Authors:  R A Lerner; R J Glassock; F J Dixon
Journal:  J Am Soc Nephrol       Date:  1999-06       Impact factor: 10.121

2.  Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions.

Authors:  J H Stone; M Talor; J Stebbing; M L Uhlfelder; N R Rose; K A Carson; D B Hellmann; C L Burek
Journal:  Arthritis Care Res       Date:  2000-12

Review 3.  Complement therapeutics; history and current progress.

Authors:  B Paul Morgan; Claire L Harris
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

Review 4.  Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.

Authors:  H-P Hartung; L Mouthon; R Ahmed; S Jordan; K B Laupland; S Jolles
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

5.  Eculizumab treatment for rescue of renal function in IgA nephropathy.

Authors:  Therese Rosenblad; Johan Rebetz; Martin Johansson; Zivile Békássy; Lisa Sartz; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2014-06-13       Impact factor: 3.714

6.  Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice.

Authors:  Marielle A Otten; Tom W L Groeneveld; Roelof Flierman; Maria Pia Rastaldi; Leendert A Trouw; Maria C Faber-Krol; Annemieke Visser; Maria C Essers; Jill Claassens; J Sjef Verbeek; Cees van Kooten; Anja Roos; Mohamed R Daha
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

7.  Serum complement pattern in essential mixed cryoglobulinaemia.

Authors:  A Tarantino; A Anelli; A Costantino; A De Vecchi; G Monti; L Massaro
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

8.  Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease.

Authors:  Sophie Ohlsson; Hans Herlitz; Sigrid Lundberg; Daina Selga; Johan Mölne; Jörgen Wieslander; Mårten Segelmark
Journal:  Am J Kidney Dis       Date:  2013-11-01       Impact factor: 8.860

Review 9.  Update on pathogenic mechanisms of systemic necrotizing vasculitis.

Authors:  Maria I Danila; S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2008-12       Impact factor: 4.592

10.  C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage.

Authors:  Claudia Duehrkop; Yara Banz; Rolf Spirig; Sylvia Miescher; Marc W Nolte; Martin Spycher; Richard A G Smith; Steven H Sacks; Robert Rieben
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

View more
  20 in total

1.  Early decreased plasma levels of factor B and C5a are important biomarkers in children with Kawasaki disease.

Authors:  Qing-Mei Zou; Xiao-Hui Li; Rui-Xia Song; Nan-Ping Xu; Ting Zhang; Ming-Ming Zhang; Yao Lin; Lin Shi; Jin Fu; Xiao-Dai Cui
Journal:  Pediatr Res       Date:  2015-05-04       Impact factor: 3.756

Review 2.  Epigenetics and Vasculitis: a Comprehensive Review.

Authors:  Paul Renauer; Patrick Coit; Amr H Sawalha
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

Review 3.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

4.  Characteristics of immune function in the acute phase of Henoch-Schönlein purpura.

Authors:  Yan Ding; Yang Zhou; Hua-Rong Li; Yue-Hua Xiong; Wei Yin; Lei Zhao
Journal:  Clin Rheumatol       Date:  2021-03-29       Impact factor: 2.980

5.  Arteriovenous Fistula Nonmaturation: What's the Immune System Got to Do with It?

Authors:  Crystal A Farrington; Gary Cutter; Michael Allon
Journal:  Kidney360       Date:  2021-09-14

Review 6.  Autoimmunity in 2014.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

Review 7.  Autoimmunity in 2015.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

Review 8.  Ocular Involvement in Systemic Autoimmune Diseases.

Authors:  Elena Generali; Luca Cantarini; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

Review 9.  Signal transduction mechanism of exosomes in diabetic complications (Review).

Authors:  Xueting Li; Shuo Shi; Dehuai Jing; Xinjian Li; Bin Zhang; Qingli Bie
Journal:  Exp Ther Med       Date:  2021-12-17       Impact factor: 2.447

10.  Cutaneous Vasculitis and Recurrent Infection Caused by Deficiency in Complement Factor I.

Authors:  Sira Nanthapisal; Despina Eleftheriou; Kimberly Gilmour; Valentina Leone; Radhika Ramnath; Ebun Omoyinmi; Ying Hong; Nigel Klein; Paul A Brogan
Journal:  Front Immunol       Date:  2018-04-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.